Details

Title
Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
Author
Powderly, John; Cote, Gregory; Flaherty, Keith; Szmulewitz, Russell Z; Ribas, Antoni; Weber, Jeffrey; Loo, Deryk; Baughman, Jan; Chen, Francine; Moore, Paul; Bonvini, Ezio; Vasselli, James; Wigginton, Jon; Cohen, Roger; Burris, Howard; Chmielowski, Bartosz
Section
Oral Presentation
Publication year
2015
Publication date
Nov 2015
Publisher
BMJ Publishing Group LTD
e-ISSN
20511426
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1186/2051-1426-3-S2-O8
ProQuest document ID
2638111560
Copyright
© 2015 Powderly et al. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.